FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308349064> ?p ?o ?g. }

• W4308349064 endingPage "340" @default.
• W4308349064 startingPage "329" @default.
• W4308349064 abstract "Background Reducing treatment burden is a priority for people with cystic fibrosis, whose health has benefited from using new modulators that substantially increase CFTR protein function. The SIMPLIFY study aimed to assess the effects of discontinuing nebulised hypertonic saline or dornase alfa in individuals using the CFTR modulator elexacaftor plus tezacaftor plus ivacaftor (ETI). Methods The SIMPLIFY study included two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials at 80 participating clinics across the USA in the Cystic Fibrosis Therapeutics Development Network. We included individuals with cystic fibrosis aged 12–17 years with percent predicted FEV1 (ppFEV1) of 70% or more, or those aged 18 years or older with ppFEV1 of 60% or more, if they had been taking ETI and either (or both) mucoactive therapies (≥3% hypertonic saline or dornase alfa) for at least 90 days before screening. Participants on both hypertonic saline and dornase alfa were randomly assigned to one of the two trials, and those on a single therapy were assigned to the applicable trial. All participants were then randomly assigned 1:1 to continue or discontinue therapy for 6 weeks using permuted blocks of varying size, stratified by baseline ppFEV1 (week 0; ≥90% or <90%), single or concurrent use of hypertonic saline and dornase alfa, previous SIMPLIFY study participation (yes or no), and age (≥18 or <18 years). For participants randomly assigned to continue their therapy during a given trial, this therapy was instructed to be taken at least once daily according to each participant's pre-existing, clinically prescribed regimen. Hypertonic saline concentration was required to be at least 3%. The primary objective for each trial was to determine whether discontinuing was non-inferior to continuing, measured by the 6-week change in ppFEV1 in the per-protocol population. We established a non-inferiority margin of –3% for the difference between groups in the 6-week change in ppFEV1. Safety outcomes were analysed in the intention-to-treat population. This study is registered with ClinicalTrials.gov, NCT04378153. Findings From Aug 25, 2020, to May 25, 2022, a total of 672 unique participants were screened for eligibility for one or both trials, resulting in 847 total random assignments across both trials with 594 unique participants. 370 participants were randomly assigned in the hypertonic saline trial and 477 in the dornase alfa trial. Participants across both trials had an average ppFEV1 of 96·9%. Discontinuing treatment was non-inferior to continuing treatment with respect to the absolute 6-week change in ppFEV1 in both the hypertonic saline trial (–0·19% [95% CI –0·85 to 0·48] in the discontinuation group [n=133] vs 0·14% [–0·51 to 0·78] in the continuation group [n=140]; between-group difference –0·32% [–1·25 to 0·60]) and dornase alfa trial (0·18% [–0·38 to 0·74] in the discontinuation group [n=199] vs –0·16% [–0·73 to 0·41] in the continuation group [n=193]; between-group difference 0·35% [–0·45 to 1·14]), with consistent results in the intention-to-treat populations. In the hypertonic saline trial, 64 (35%) of 184 in the discontinuation group versus 44 (24%) of 186 participants in the continuation group and, in the dornase alfa trial, 89 (37%) of 240 in the discontinuation group versus 55 (23%) of 237 in the continuation group had at least one adverse event. Interpretation In individuals with cystic fibrosis on ETI with relatively well preserved pulmonary function, discontinuing daily hypertonic saline or dornase alfa for 6 weeks did not result in clinically meaningful differences in pulmonary function when compared with continuing treatment." @default.
• W4308349064 created "2022-11-11" @default.
• W4308349064 creator A5000649997 @default.
• W4308349064 creator A5000689696 @default.
• W4308349064 creator A5001574414 @default.
• W4308349064 creator A5002171420 @default.
• W4308349064 creator A5002482790 @default.
• W4308349064 creator A5003117391 @default.
• W4308349064 creator A5003461290 @default.
• W4308349064 creator A5003559190 @default.
• W4308349064 creator A5003565749 @default.
• W4308349064 creator A5005287178 @default.
• W4308349064 creator A5005909091 @default.
• W4308349064 creator A5005939233 @default.
• W4308349064 creator A5006251710 @default.
• W4308349064 creator A5006523632 @default.
• W4308349064 creator A5008059668 @default.
• W4308349064 creator A5008902039 @default.
• W4308349064 creator A5009193428 @default.
• W4308349064 creator A5010385510 @default.
• W4308349064 creator A5010530707 @default.
• W4308349064 creator A5010914504 @default.
• W4308349064 creator A5010924080 @default.
• W4308349064 creator A5011381489 @default.
• W4308349064 creator A5012325583 @default.
• W4308349064 creator A5012586547 @default.
• W4308349064 creator A5013057484 @default.
• W4308349064 creator A5013118084 @default.
• W4308349064 creator A5013167596 @default.
• W4308349064 creator A5014073994 @default.
• W4308349064 creator A5014503990 @default.
• W4308349064 creator A5014630184 @default.
• W4308349064 creator A5015548603 @default.
• W4308349064 creator A5015765237 @default.
• W4308349064 creator A5016150481 @default.
• W4308349064 creator A5016988378 @default.
• W4308349064 creator A5017024281 @default.
• W4308349064 creator A5017118271 @default.
• W4308349064 creator A5017830229 @default.
• W4308349064 creator A5018789631 @default.
• W4308349064 creator A5018824031 @default.
• W4308349064 creator A5019029104 @default.
• W4308349064 creator A5019177511 @default.
• W4308349064 creator A5019729415 @default.
• W4308349064 creator A5020267507 @default.
• W4308349064 creator A5020767172 @default.
• W4308349064 creator A5021088668 @default.
• W4308349064 creator A5021526602 @default.
• W4308349064 creator A5021891207 @default.
• W4308349064 creator A5021936611 @default.
• W4308349064 creator A5022571835 @default.
• W4308349064 creator A5022638977 @default.
• W4308349064 creator A5022875434 @default.
• W4308349064 creator A5023404491 @default.
• W4308349064 creator A5023417071 @default.
• W4308349064 creator A5023708911 @default.
• W4308349064 creator A5023951605 @default.
• W4308349064 creator A5023964786 @default.
• W4308349064 creator A5024322723 @default.
• W4308349064 creator A5024947987 @default.
• W4308349064 creator A5025317516 @default.
• W4308349064 creator A5025553034 @default.
• W4308349064 creator A5025851014 @default.
• W4308349064 creator A5027118818 @default.
• W4308349064 creator A5027169423 @default.
• W4308349064 creator A5027247407 @default.
• W4308349064 creator A5028031386 @default.
• W4308349064 creator A5028251230 @default.
• W4308349064 creator A5028877633 @default.
• W4308349064 creator A5029091133 @default.
• W4308349064 creator A5030022120 @default.
• W4308349064 creator A5031198323 @default.
• W4308349064 creator A5031205333 @default.
• W4308349064 creator A5031331141 @default.
• W4308349064 creator A5031900147 @default.
• W4308349064 creator A5031909028 @default.
• W4308349064 creator A5032614384 @default.
• W4308349064 creator A5033038489 @default.
• W4308349064 creator A5033623131 @default.
• W4308349064 creator A5033956429 @default.
• W4308349064 creator A5034401270 @default.
• W4308349064 creator A5034915610 @default.
• W4308349064 creator A5034933862 @default.
• W4308349064 creator A5037168536 @default.
• W4308349064 creator A5038887111 @default.
• W4308349064 creator A5038956345 @default.
• W4308349064 creator A5039443547 @default.
• W4308349064 creator A5039726678 @default.
• W4308349064 creator A5040461519 @default.
• W4308349064 creator A5040463490 @default.
• W4308349064 creator A5040480470 @default.
• W4308349064 creator A5040567672 @default.
• W4308349064 creator A5040666131 @default.
• W4308349064 creator A5041152291 @default.
• W4308349064 creator A5041544508 @default.
• W4308349064 creator A5041959864 @default.
• W4308349064 creator A5043256275 @default.
• W4308349064 creator A5043288625 @default.

• next